An autopsy case report of fulminant myocarditis: Following mRNA COVID-19 vaccination

Hoshino, Naoki; Ichiyasu, Taisuke; Kuwahara, K.; Kawai, Hideki; Muramatsu, Takashi; Ishii, Hideki; Tsukamoto, Tetsuya; Morimoto, Shinichiro; Izawa, Hideo

doi:10.1016/j.jccase.2022.06.006

Cited by 12 publications

(24 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, out of 50 hospitalized patients that took part in this review, only 3 were female (6%) and 47 patients were male (94%). Therefore, there seems to be a predisposition to suffer from vaccine-related myocarditis in males among this population dataset (8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22). Furthermore, the mean age was 25.6 years old, the mode was 23 years old, and the median age was 24.5 years old.…”

Section: Resultsmentioning

confidence: 92%

“…Thus, vaccinationassociated myocarditis tends to affect more young adults in general. Additionally, 77.5% of cases started presenting symptoms of myocarditis after receiving the 2 nd dose, whereas patients who received the 1 st dose (20.4%) started having symptoms such as chest pain and fever, and there was only one patient who had the 3 rd dose (2.04%) and began noticing some adverse effects (8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22). Hence, most people are more propense to start developing symptoms for myocarditis after taking the 2 nd dose of the COVID-19 vaccine.…”

Section: Resultsmentioning

confidence: 99%

“…Treatment for myocarditis included medication to improve the heart function; patients were treated with beta-blockers, non-steroidal anti-inflammatory drugs (NSAIDs), and corticosteroids drugs. Some other therapeutic treatment options were ACE inhibitors, angiotensin-converting enzyme inhibitor, omeprazole, bisoprolol, ramipril and activity restriction was also recommended (8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22). Even though prognosis is good with majority of patients have been recovered in a few days after hospital admission (96%), only 2 patients died (4%).…”

Section: Demographics Of Patients Diagnosed With Vaccine-related Myoc...mentioning

confidence: 99%

“…On average, it takes approximately 4 days for patients to start showing symptoms of myocarditis after vaccination. In addition, hospitalized patients often had the following symptoms: chest pain, fever, palpitations, fatigue, and dyspnea (8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22). Moreover, PCR tests were performed and all of them were negative for SARS-COV-2 in all patients that took part in this review.…”

Section: Demographics Of Patients Diagnosed With Vaccine-related Myoc...mentioning

confidence: 99%

“…Additional PCR test results for other viruses such as influenza and coxsackies virus were also negative, ruling out other possible aetiologias of myocarditis. In most cases, echocardiography (ECHO) results showed that the left ventricular ejection fraction (LVEF) was greater than or equal to 50% (8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22). While electrocardiogram (ECG) results revealed some abnormalities such as: paroxysmal atrioventricular block, lateral ST elevations in V3-V6 and in some cases there were no signs of acute ischemia.…”

Section: Demographics Of Patients Diagnosed With Vaccine-related Myoc...mentioning

confidence: 99%

See 4 more Smart Citations

Immunization-associated myocarditis post mRNA COVID-19 vaccination: a review article

Núñez

2022

View full text Add to dashboard Cite

Introducción: Miocarditis ha sido reportada como un efecto secundario de la vacuna del COVID-19 de ARNm. En este artículo de revisión, 15 casos clínicos confirmados de miocarditis asociados con la vacuna del COVID-19 de diferentes lugares del mundo fueron resumidos. Objetivos: El objetivo principal de este artículo es de críticamente analizar y resumir la información existente sobre la asociación de la vacunación del COVID-19 y el desarrollo de miocarditis como efecto secundario de la vacuna. Metodología: Google Académico fue usado para buscar casos confirmados de miocarditis relacionados a la vacuna del COVID-19 desde el 2021 hasta el 2022. Resultados: existe mayor predominancia de miocarditis en jóvenes adultos, especialmente en pacientes de sexo masculino (94%). Defectos genéticos, aspectos ambientales y hábitos alimenticios, fueron encontrados como otros posibles factores que pudieron haber estimulado el desarrollo de miocarditis. Los niveles de troponina y la proteína C-reactiva estuvieron elevados en la mayoría de los casos (93%). Conclusiones: Los casos de miocarditis asociados con la vacuna del COVID-19 son muy escasos y representan una mínima fracción de toda la población vacunada. Los beneficios que ofrece la vacuna del COVID-19 son mucho mayores a los efectos que una infección por COVID-19 podría causar. Se recomienda seguir administrando la vacuna del COVID-19 para hacer frente a la pandemia del coronavirus.

show abstract

Section: Resultsmentioning

confidence: 92%

Section: Resultsmentioning

confidence: 99%

Section: Demographics Of Patients Diagnosed With Vaccine-related Myoc...mentioning

confidence: 99%

Section: Demographics Of Patients Diagnosed With Vaccine-related Myoc...mentioning

confidence: 99%

Section: Demographics Of Patients Diagnosed With Vaccine-related Myoc...mentioning

confidence: 99%

See 3 more Smart Citations

Immunization-associated myocarditis post mRNA COVID-19 vaccination: a review article

Núñez

2022

View full text Add to dashboard Cite

show abstract

Autopsy findings in cases of fatal COVID‐19 vaccine‐induced myocarditis

Hulscher,

Hodkinson,

Makis

et al. 2024

ESC Heart Failure

View full text Add to dashboard Cite

COVID‐19 vaccines have been linked to myocarditis, which, in some circumstances, can be fatal. This systematic review aims to investigate potential causal links between COVID‐19 vaccines and death from myocarditis using post‐mortem analysis. We performed a systematic review of all published autopsy reports involving COVID‐19 vaccination‐induced myocarditis through 3 July 2023. All autopsy studies that include COVID‐19 vaccine‐induced myocarditis as a possible cause of death were included. Causality in each case was assessed by three independent physicians with cardiac pathology experience and expertise. We initially identified 1691 studies and, after screening for our inclusion criteria, included 14 papers that contained 28 autopsy cases. The cardiovascular system was the only organ system affected in 26 cases. In two cases, myocarditis was characterized as a consequence from multisystem inflammatory syndrome. The mean age of death was 44.4 years old. The mean and median number of days from last COVID‐19 vaccination until death were 6.2 and 3 days, respectively. We established that all 28 deaths were most likely causally linked to COVID‐19 vaccination by independent review of the clinical information presented in each paper. The temporal relationship, internal and external consistency seen among cases in this review with known COVID‐19 vaccine‐induced myocarditis, its pathobiological mechanisms, and related excess death, complemented with autopsy confirmation, independent adjudication, and application of the Bradford Hill criteria to the overall epidemiology of vaccine myocarditis, suggests that there is a high likelihood of a causal link between COVID‐19 vaccines and death from myocarditis.

show abstract

Elasomeran

2023

Reactions Weekly

View full text Add to dashboard Cite

An autopsy case report of fulminant myocarditis: Following mRNA COVID-19 vaccination

Cited by 12 publications

References 10 publications

Immunization-associated myocarditis post mRNA COVID-19 vaccination: a review article

Immunization-associated myocarditis post mRNA COVID-19 vaccination: a review article

Autopsy findings in cases of fatal COVID‐19 vaccine‐induced myocarditis

Elasomeran

Contact Info

Product

Resources

About